A Post Marketing Survey Study to Evaluate the Safety and Effectiveness of Prezista

• Status: Completed
• Trial end date: 2016-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess the safety data of darunavir in a natural clinical practice.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Janssen Korea, Ltd., Korea
• Treatments: Darunavir

Criteria

Inclusion Criteria:

• Patients who are prescribed with darunavir for treatment of Acquired Immune Deficiency Syndrome (AIDS)

Exclusion Criteria:

• Known hypersensitivity to Prezista

• Prezista coadministered with medicinal products that are highly dependent on CYP3A for clearance